External and internal radiation therapy: Past and future directions

Journal of Cancer Research and Therapeutics

Volumn 6, Issue 3, 2010, Pages 239-248

  Sadeghi, Mahdi ^a   Enferadi, Milad ^b   Shirazi, Alireza ^c  

^a AGRICULTURAL MEDICAL AND INDUSTRIAL RESEARCH SCHOOL   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Boron neutron capture therapy; intensity modulated radiation therapy; linac; peptide receptor radionuclide therapy; radioimmunotherapy; targeted radionuclide therapy

Indexed keywords

ACTINIUM 225; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BISMUTH 212; BISMUTH 213; BLEOMYCIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; COPPER 67; IBRITUMOMAB TIUXETAN; IODINE 131; LEAD 212; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; MONOCLONAL ANTIBODY HER 2; MONOCLONAL ANTIBODY J591; OCTREOTIDE; PEMTUMOMAB; PEPTIDE; RADIOISOTOPE; RADIUM; RADIUM 223; RADIUM 224; RHENIUM 188; SAMARIUM 153; SOMATOSTATIN DERIVATIVE; STRONTIUM 89; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ALPHA RADIATION; BEAM THERAPY; BETATRON; BRACHYTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CYBERKNIFE; CYCLOTRON; ELECTRON; ENDORADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERNAL BEAM RADIOTHERAPY; ISOTOPE LABELING; LINEAR ACCELERATOR; LIVER TUMOR; LUNG CANCER; MAGNETIC RESONANCE ANGIOGRAPHY; MOUTH CANCER; NEOPLASM; NEUTRON CAPTURE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEURA TUMOR; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOIMMUNOTHERAPY; RADIOSURGERY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINAL CORD TUMOR; STEREOTACTIC BODY RADIATION THERAPY; SYNCHROTRON; TARGETED RADIONUCLIDE THERAPY; TOMOTHERAPY; UTERINE CERVIX CANCER; UTERUS CANCER; VOLUMETRIC MODULATED ARC THERAPY; X RAY;

HUMANS; NEOPLASMS; RADIOTHERAPY;

EID: 78650092311     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.73324     Document Type: Review

References (104)

1. Symonds RP, Foweraker K. Principles of chemotherapy and radiotherapy. Curr Obstet Gynaecol 2006;16:100-6.
2. Sridhar T, Symonds RP. Principles of chemotherapy and radiotherapy. Obstet Gynaecol Repro Med 2009;19:61-7.
3. Mothersill C, Seymour C. Radiation-induced bystander effects: Past history and future directions. Radiat Res 2001;155:759-67.
4. Mothersill C, Seymour CB. Radiation-induced bystander effects: Implications for cancer. Nat Rev Cancer 2004;4:158-64.
5. Lyng FM, Seymour CB, Mothersill C. Early events in the apoptotic cascade initiated in cells treated with medium from the progeny of irradiated cells. Radiat Prot Dosimetry 2002;99:169-72.
6. Boudaïffa B, Cloutier P, Hunting D, Huels MA, Sanche L. Resonant formation of DNA strand breaks by low-energy (3 to 20 eV) electrons. Science 2000;287:1658-60.
7. Martin F, Burrow PD, Cai Z, Cloutier P, Hunting D, Sanche L. DNA strand breaks induced by 0-4 eV electrons: The role of shape resonances. Phys Rev 2004;93:068101.
8. Nikjoo H, Emfietzoglou D, Watanabe R, Uehara S. Can Monte Carlo track structure codes reveal reaction mechanism in DNA damage and improve radiation therapy? Radiat Phys Chem 2008;77:1270-9.
9. Jonathan EC, Bernhard EJ, McKenna WG. How does radiation kill cells? Curr Opin Chem Biol 1999;3:77-83.
10. Symonds RP. Recent advances in radiotherapy. BMJ 2001;323:1107-10.
11. Boyd M, Ross SC, Dorrens J, Fullerton NE, Zalutsky MR, Mairs RJ. Radiation induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and Auger electron-emitting radionuclides. J Nucl Med 2006;47:1007-15.
12. Dale RG, Jones B, Cαrabe-Fernαndez A. Why more needs to be known about RBE effects in modern radiotherapy? Appl Radiat Isot 2009;67:387-92.
13. Khan F. Handbook of the physics of radiation therapy. Baltimore: Williams and Wilkins; 2009. p. 36-53.
14. Kassis AI. Radiotargeting agents for cancer therapy. Expert Opin Drug Deliv 2005;2:981-91.
15. Podgorsak E. Review of Radiation Oncology Physics: A Handbook for Teachers and Students. Vienna: IAEA; 2003. p. 179-98.
16. Mackie TR. Radiation therapy treatment optimization. Semin Radiat Oncol 1999;9:1-3.
17. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996;14:3156-74.
18. Schlyer DJ, Van den Winkel P, Ruth TJ, Vora MM. Cyclotron produced radionuclides: Principles and practice. Technical Reports Series No. 465, Vienna: IAEA; 2008. p. 31-57.
19. Lewis RA. Medical applications of synchrotron radiation in Australia. Nucl Instrum Methods Phys Res A 2005;548:23-9. Available from: http://www.synchrotron.vic.gov.au [last cited on 2010 Mar 1].
20. Blattmann H, Gebbers J, Brauer-Krisch E, Bravin A, Le Du G, Burkar W, et al. Applications of synchrotron X-rays to radiotherapy. Nucl Instrum Methods Phys Res A 2005;548:17-22.
21. Hiramoto K, Umezawa M, Saito K, Tootake S, Nishiuchi H, Tanaka SH, et al. The synchrotron and its related technology for ion beam therapy. Nucl Instrum Methods Phys Res B 2007;261:786-90.
22. Badano L, Benedikt M, Bryant P, Crescenti M, Holy P, Knaus P, et al. Synchrotrons for hadron therapy: Part I. Nucl Instrum Methods Phys Res A 1999;430:512-22.
23. Thomlinson W, Suortti P, Chapman D. Recent advances in synchrotron radiation medical research. Nucl Instrum Methods Phys Res A 2005;543:288-96.
24. Zelefsky MJ, Fuks Z, Leibel SA. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 2002;12:229-37.
25. Van Houtte P. New potentials of radiotherapy in non-small cell lung cancer: Stereotactic therapy and IMRT. Curr Probl Cancer 2003;27:60-3.
26. Fogliata A, Nicolini G, Alber M, Asell M, Dobler B, El-haddad M, et al. IMRT for breast. A planning study. Radiother Oncol 2005;76:300-10.
27. Alongi F, Fiorino C, Cozzarin C, Broggid S, Pernad L, Cattaneo GM, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 2009;93:207-12.
28. Beriwal S, Kim H, Coon D, Mogus R, Heron DE, Li X, et al. Intensitymodulated radiotherapy for the treatment of vulvar carcinoma: A comparative dosimetric study with early clinical outcome. Int J Radiat Oncol Biol Phys 2006;64:1395-400.
29. Van de Bunt L, Van der Heide UA, Ketelaars M, de Kort GA. Conventional, conformal and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. Int J Radiat Oncol Biol Phys 2006;64:189-96.
30. Morgia G, De Renzis C. CyberKnife in the treatment of prostate cancer: A revolutionary system. Eur Urol 2008;56:40-2.
31. Adler JR. CyberKnife radiosurgery for brain and spinal tumors. Int Congr Ser 2002;1247:545-52.
32. Suzuki M, Endo K, Satoh H, Sakurai Y, Kumada H, Kimura H, et al. A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT). Radiother Oncol 2008;88:192-5.
33. Zonta A, Pinelli T, Prati U, Roveda L, Ferrari C, Clerici AM, et al. Extra-corporeal liver BNCT for the treatment of diffuse metastases: What was learned and what is still to be learned. Appl Radiat Isot 2009;67:S67-75.
34. Suzuki M, Tanaka H, Sakurai Y, Kashino G, Yong L, Masunaga S, et al. Impact of accelerator-based boron neutron capture therapy (AB-BNCT) on the treatment of multiple liver tumors and malignant pleural mesothelioma. Radiother Oncol 2009;92:89-95.
35. Nakai K, Kumada H, Yamamoto T, Tsurubuchi T, Zaboronok A, Matsumura A, et al. Feasibility of boron neutron capture therapy for malignant spinal tumors. Appl Radiat Isot 2009;67:S43-6.
36. Barth RF, Joensuu H. Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: As effective, more effective or less effective than photon irradiation. Radiother Oncol 2007;82:119-22.
37. Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, et al. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot 2009;67:S37-42.
38. Kimura Y, Ariyoshi Y, Shimahara M, Miyatake S, Kawabata S, Ono K, et al. Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node. Appl Radiat Isot 2009;67:S47-9.
39. Pozzi E, Nigg DW, Miller M, Thorp SI, Heber EM, Zarza L, et al. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: Application to the treatment of
40. Wittig A, Collette L, Moss R, Sauerwein WA. Early clinical trial concept for boron neutron capture therapy: A critical assessment of the EORTC trial 11001. Appl Radiat Isot 2009;67:S59-62.
41. Bendel P, Wittig A, Basilico F, Mauri PL, Sauerwein W. Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients-Results from EORTC trial 11001. J Pharma Biomed Anal 2010;51:284-7.
42. Nag S, Dobelbower R, Glasgow G, Gustafson G, Syed N, Thomadsen B, et al. Inter-society standards for the performance of brachytherapy: A joint report from ABS, ACMP and ACRO. Crit Rev Oncol Hematol 2003;48:1-17.
43. Regueiro C. Brachytherapy: Basic concepts, current clinical indications and future perspectives. Rev Oncol 2002;4:512-6.
44. Loeb S, Nadler RB. Management of the complications of external beam radiotherapy and brachytherapy. Curr Urol Rep 2006;7:200-8.
45. Saito S, Nagata H, Kosugi M, Toya K. Brachytherapy with permanent seed implantation. Int J Clin Oncol 2007;12:395-7.
46. Broens P, Van Limbergen E, Penninckx F. Clinical and manometric effects of combined external beam irradiation and brachytherapy for anal cancer. Int J Colorectal Dis 1998;13:68-72.
47. Julow J, Viola A, Majo T, Valαlik I, Sαgi S, Mange L, et al. Iodine-125 brachytherapy of brain stem tumors. Strahlenther Onkol 2004;180:449-54.
48. John M, Shroff S, Farb A, Virmani R. Local arterial responses to 32 P β-emitting stents. Cardio Radiat Med 2001;2:143-50.
49. Golombeck M, Heise S, Schloesser K, Schuessler B, Schweickert H. Intravascular brachytherapy with radioactive stents produced by ion implantation. Nucl Inst Meth Phys Res 2003;206:495-500.
50. Sioshansi P, Bricault R. Low energy 103Pd gamma (X-ray) source for vascular brachytherapy. Cardio Radiat Med 1999;3:278-87.
51. Saxena SK, Sharma SD, Dash A, Venkatesh M. Development of a new design 125 I-brachytherapy seed for its application in the treatment of eye and prostate cancer. Appl Radiat Isot 2009;67:1421-5.
52. 169Tm(d,2n) reaction for production of the therapeutic radionuclide 169 Yb. Appl Radiat Isot 2007; 65: 663-8.
53. O'Donnell RT. Nuclear localizing sequences: An innovative way to improve targeted radiotherapy. J Nucl Med 2006;47:738-9.
54. Flower MA. Targeted radiotherapy review meeting. Br J Radiol 1997;70:875-7.
55. Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. Eur J Cancer 2006;42:994-1003.
56. Li S, Beheshti M. The radionuclide molecular imaging and therapy of neuroendocrine tumors. Curr Cancer Drug Targets 2005;5:139-48.
57. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol 1996;41:1905-14.
58. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005;46:4S-12S.
59. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: Assessment of progress and problems. Radiother Oncol 2003;66:107-17.
60. Murray D, Mcewan AJ. Radiobiology of systemic radiation therapy. Cancer Biother Radiopharm 2007;22:1-23.
61. Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR. Therapeutic radionuclides: Production and decay property considerations. J Nucl Med 1991;32:174-85.
62. Thisgaard H. Accelerator based production of Auger electron emitting isotopes for radionuclide therapy. Riso-PhD-42(EN) PhD Thesis, Faculty of Life Science, Denmark: University of Copenhagen; p. 4-6.
63. Verheijen RH, Massuger LF, Benigno BB, Epenetos AA, Lopes A, Soper JT, et al. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 with epithelial ovarian cancer after a surgically defined complete remission. J Clin Oncol 2006;24:571-8.murine monoclonal antibody in patients
64. Los M. New, exciting developments in experimental therapies in the early 21st century. Eur J Pharmacol 2009;625:1-5.
65. Rösch F Radiolanthanides in endoradiotherapy: An overview. Radiochim Acta 2007; 95: 303-11.
66. Zoller F, Eisenhut M, Haberkorn U, Mier W. Endoradiotherapy in cancer treatment-Basic concepts and future trends. Eur J Pharmacol 2009;625:55-62.
67. Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ, Kassis AI. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res 1998;150:263-8.
68. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: Absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994;35:303-16.
69. Kassis AI, Harris CR, Adelstein SJ, Ruth TJ, Lambrecht R, Wolf AP. The in vitro radiobiology of astatine-211 decay. Radiat Res 1986;105:27-36.
70. Bloomer WD, McLaughlin WH, Lambrecht RM, Atcher RW, Mirzadeh S, Madara JL, et al. 211 At radiocolloid therapy further observations and comparison with radiocolloids of 32 P, 165 Dy, and 90 Y. Int J Radiat Oncol Biol Phys 1984;10:341-8.
71. EXFOR, Nuclear reaction data, EXFOR is accessed on line at Available from: http://www.nndc.bnl.gov/exfor/exfor00.htm [last cited on2009].
72. IAEA-TECDOC-1340. Manual of Reactor Produced Radioisotopes. Vienna, Austria, 2003.
73. Table of Radioactive Isotopes. Version 2.1. 2004 Available from: http://www.ie.lbl.gov/toi/[last accessed on 2010 Mar 1].
74. Pillai MR, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N. Production logistics of 177 Lu for radionuclide therapy. Appl Radiat Isot 2003;59:109-18.
75. Al-Abyad M, Spahn I, Sudαr S, Morsy M, Comsan MN, Csikai J, et al. Nuclear data for production of the therapeutic radionuclides 32 P, 64 Cu, 67 Cu, 89 Sr, 90 Y and 153 Sm via the (n,p) reaction: Evaluation of excitation unction and its validation via integral cross-section measurement using a 14 MeV d(Be) neutron source. Appl Radiat Isot 2006;64:717-24.
76. Mirzadeh S, Mausner LF, Garland MA. Reactor produced medical radionuclides. Handbook of Nuclear Chemistry. Dordredht, Netherland: Kluwer Academic Publishers; 2003. p. 1-4.
77. Qaim SM. Therapeutic radionuclides and nuclear data. Radiochim Acta 2001;89:297-9.
78. Thisgaard H, Jensen M. 119 Sb-a potent Auger emitter for targeted radionuclide therapy. Med Phys 2008;35:3839-46.
79. Thisgaard H, Jensen M. Production of the Auger emitter 119 Sb for targeted radionuclide therapy using a small PET-cyclotron. Appl Radiat Isot 2008;67:34-8.
80. Behr TM, Béhé M, Löhr M, Sgouros G, Angerstein C, Wehrmann E, et al. Therapeutic advantages of Auger electron-over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000;27:753-65.
81. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Lowenergy electron emitters for targeted radiotherapy of small tumours. Acta Oncologica 2001;40:602-8.
82. O'Donoghuey JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol 1996;41:1973-92.
83. Nikjoo H, Girard P, Charlton DE, Hofer KG, Laughton CA. Auger electrons-A nanoprobe for structural, molecular and cellular. Radiat Prot Dosimetry 2006;122:72-9.
84. Kassis AI. Cancer therapy with Auger electrons: Are we almost there? J Nucl Med 2003;44:1479-81.
85. Buchegger F, Perillo-Adamer F, Dupertuis YM, Delaloye AB. Auger radiation targeted into DNA: A therapy perspective. Eur J Nucl Med Mol Imaging 2006;33:1352-63.
86. Adelstein SJ, Kassis AI, Bodei L, Mariani G. Radiotoxicity of iodine-125 and other Auger-electron-emitting radionuclides: Background to therapy. Cancer Biother Radiopharm 2003;18:301-15.
87. IAEA-Technical Reports Series No. 468. Cyclotron produced radionuclides: Physical characteristics and production methods. Vienna, 2009. p. 58-60.
88. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
89. Reilly RM. Biopharmaceuticals as targeting vehicles for in situ radiotherapy of malignancies. Weinheim: Wiley-VCH Verlag GmbH and Co; 2005. p. 497-35.
90. Costantini D. Targeted Auger electron radiotherapy of HER2-amplified breast cancer. Toronto, Canada: Graduate Department of Pharmaceutical Sciences University of Toronto; 2009. p. 16-23.
91. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005;20:557-68.
92. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res 1994;54:4719-25.
93. Tolmachev V, Bernhardt P, Forssell-Aronsson E, Lundqvist H. 114mIn, a candidate for radionuclide therapy: Low-energy cyclotron production and labeling of DTPA-D-Phe1-octreotide. Nucl Med Biol 2000;27:183-8.
94. Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 2008;23:3-24.
95. Rajendran J. Radioimmunotherapy for the 21st century: An old approach with a new paradigm. Indian J Nucl Med 2004;19:81-8.
96. Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: Current status and future directions. Eur J Nucl Med 2003;30:463-9.
97. Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005;19:595-616.
98. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors, peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007;21:111-29.
99. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
100. Rolleman EJ. Kidney protection during peptide receptor radionuclide therapy. Rotterdam: Department of Nuclear Medicine Erasmus MC; 2007. p. 18-31.
101. Van Essen M, Krenning EP, Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46:723-34.
102. Ginj M, Hinni K, Tschumi S, Schulz S, Maecke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med 2005;46:2097-103.
103. Okarvi SM. Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer. Cancer Treat Rev 2008;34:13-26.
104. Jääskelä Saari H. Auger-emitter radiochemotherapy in squamous cell cancers: In vitro and in vivo experiments with In-BLMC. Department of otorhinolaryngology-head and neck surgery. University of helsinki and university of turku, Helsinki 11-58. Available from: http://www.ethesis. helsinki.fi [last accessed on 2009].